Incannex股价在睡眠呼吸暂停试验结果积极后大涨

英为财情

2025/08/08

Investing.com -- Incannex Healthcare Inc. (NASDAQ:IXHL)股价周五上涨10%，此前该公司发布了其阻塞性睡眠呼吸暂停(OSA)治疗药物IHL-42X的积极第二阶段试验结果。这家临床阶段制药公司报告了其RePOSA第二阶段试验的令人信服的有效性数据，患者退出访谈显示57.6%的参与者感受到他们的OSA状况有所改善。在报告获益的患者中，89.5%描述...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2557698520"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557698520\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557698520?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-08-08 21:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557698520","market":"us","top_or_hot":-1,"title":"Incannex股价在睡眠呼吸暂停试验结果积极后大涨","media":"英为财情","content":"<div>\n<p>Investing.com -- Incannex Healthcare Inc. (NASDAQ:IXHL)股价周五上涨10%，此前该公司发布了其阻塞性睡眠呼吸暂停(OSA)治疗药物IHL-42X的积极第二阶段试验结果。\n这家临床阶段制药公司报告了其RePOSA第二阶段试验的令人信服的有效性数据，患者退出访谈显示57.6%的参与者感受到他们的OSA状况有所改善。在报告获益的患者中，89.5%描述...</p>\n\n<a href=\"https://cn.investing.com/news/stock-market-news/article-93CH-2928983\">网页链接</a>\n\n</div>\n","source":"investing_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Incannex股价在睡眠呼吸暂停试验结果积极后大涨</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIncannex股价在睡眠呼吸暂停试验结果积极后大涨\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-08-08 21:44 北京时间&nbsp;&nbsp;&nbsp;<a href=https://cn.investing.com/news/stock-market-news/article-93CH-2928983><strong>英为财情</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing.com -- Incannex Healthcare Inc. (NASDAQ:IXHL)股价周五上涨10%，此前该公司发布了其阻塞性睡眠呼吸暂停(OSA)治疗药物IHL-42X的积极第二阶段试验结果。\n这家临床阶段制药公司报告了其RePOSA第二阶段试验的令人信服的有效性数据，患者退出访谈显示57.6%的参与者感受到他们的OSA状况有所改善。在报告获益的患者中，89.5%描述...</p>\n\n<a href=\"https://cn.investing.com/news/stock-market-news/article-93CH-2928983\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4097","symbol_name":"系统软件","start_time":0,"source_url":"https://cn.investing.com/news/stock-market-news/article-93CH-2928983","article_id":"2557698520","we_media_id":null,"thumbnails":[],"rights":{"source":"investing_news","url":"https://cn.investing.com/news/stock-market-news/article-93CH-2928983","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2557698520","pubTimestamp":1754660640,"columns":[],"sourceInfo":{"source_id":"investing_news","name":"英为财情新闻"},"weMediaInfo":null,"summary":"Investing.com -- Incannex Healthcare Inc. 股价周五上涨10%，此前该公司发布了其阻塞性睡眠呼吸暂停治疗药物IHL-42X的积极第二阶段试验结果。这家临床阶段制药公司报告了其RePOSA第二阶段试验的令人信服的有效性数据，患者退出访谈显示57.6%的参与者感受到他们的OSA状况有所改善。一些患者的AHI降低幅度高达83%。Incannex总裁兼首席执行官Joel Latham表示：\"我们最近的IHL-42X第二阶段结果超出了预期。","collect":0,"end_time":0,"defaultTopTitle":"investing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4097":"系统软件","BK4167":"医疗保健技术","AHI":"ADVANCED HEALTH INTELLIGENCE LTD SPON ADS EACH REP 7 ORD SHS","IXHL":"INCANNEX HEALTHCARE LTD","BK4007":"制药"},"translate_title":"Incannex Stock Jumps After Positive Results Of Sleep Apnea Trial","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IXHL":1,"AHI":1},"content_text":"Investing.com -- Incannex Healthcare Inc. (NASDAQ:IXHL)股价周五上涨10%，此前该公司发布了其阻塞性睡眠呼吸暂停(OSA)治疗药物IHL-42X的积极第二阶段试验结果。\n这家临床阶段制药公司报告了其RePOSA第二阶段试验的令人信服的有效性数据，患者退出访谈显示57.6%的参与者感受到他们的OSA状况有所改善。在报告获益的患者中，89.5%描述这些变化对他们的日常生活有意义。\n试验在多个关键终点上显示出统计学上显著的改善。接受IHL-42X治疗的患者与安慰剂相比，呼吸暂停-低通气指数(AHI)显著降低，41.2%的高剂量接受者的AHI降低超过30%。一些患者的AHI降低幅度高达83%。\nIncannex总裁兼首席执行官Joel Latham表示：\"我们最近的IHL-42X第二阶段结果超出了预期。在一些患者中，我们观察到AHI降低高达83%，这是一个非凡的结果，也是该药物潜力的强有力信号。\"\n该治疗还表现出极佳的安全性，在治疗期间没有报告严重不良事件。大多数治疗期间出现的不良反应为轻度或中度。\n患者报告睡眠质量改善，白天嗜睡减少，认知障碍减少，以及完成日常责任更加容易。与许多睡眠药物不同，IHL-42X不会减少REM睡眠，这是记忆巩固和大脑健康的重要阶段。\n该公司资金充足，能够继续推进其临床项目，同时探索战略选择，为股东提供长期价值。\n\n本文由人工智能协助翻译。更多信息，请参见我们的使用条款。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}